Rein Therapeutics Inc. (RNTX)

Rein Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	8.54	3.22	12.87	17.31	5.19	3.6
Short-Term Investments	32.11	-	-	-	16.05	42.33
Cash & Short-Term Investments	40.65	3.22	12.87	17.31	21.24	45.93
Cash Growth	610.36%	-75.01%	-25.69%	-18.50%	-53.75%	232.73%
Prepaid Expenses	0.81	-	-	-	0.61	2.22
Restricted Cash	-	-	-	0.03	0.03	0.03
Other Current Assets	-	1.11	0.79	0.93	-	-
Total Current Assets	41.45	4.33	13.66	18.27	21.87	48.18
Property, Plant & Equipment	-	-	0	0.02	0.11	0.28
Goodwill	6.33	6.33	6.33	6.33	-	-
Other Intangible Assets	13.5	13.5	42.2	79.2	-	-
Long-Term Deferred Charges	-	-	-	2.14	-	-
Other Long-Term Assets	1.71	0	0	0.05	0.02	0.02
Total Assets	65.97	24.16	62.19	106.01	22.01	48.48

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	4.47	3.98	0.91	1.19	1.72	1.21
Accrued Expenses	1.54	2.11	4.72	2.94	1.45	3.15
Current Portion of Leases	-	-	-	0.05	0.03	0.09
Other Current Liabilities	3.7	0.1	0.12	0.21	0.18	0.06
Total Current Liabilities	9.71	6.18	5.75	4.39	3.38	4.51
Long-Term Leases	-	-	-	-	-	0.07
Long-Term Deferred Tax Liabilities	1.06	1.06	1.77	3.33	-	-
Other Long-Term Liabilities	-	-	0.28	-	-	-
Total Liabilities	10.77	7.24	7.8	7.71	3.38	4.58

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.17	0.11	0.11	0.09	0.09	0.09
Additional Paid-In Capital	423.58	373.13	360.7	295.38	291.37	289.28
Retained Earnings	-413.48	-401.27	-351.4	-288.52	-272.79	-245.46
Comprehensive Income & Other	-0.07	-0.06	-0.02	-0.06	-0.05	-0.01
Total Common Equity	10.2	-28.09	9.39	6.89	18.62	43.9
Shareholders' Equity	55.2	16.92	54.39	98.3	18.62	43.9
Total Liabilities & Equity	65.97	24.16	62.19	106.01	22.01	48.48

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	-	-	-	0.05	0.03	0.16
Net Cash (Debt)	40.65	3.22	12.87	17.27	21.21	45.77
Net Cash Growth	610.36%	-75.01%	-25.49%	-18.60%	-53.66%	241.12%
Net Cash Per Share	1.06	0.13	0.72	3.75	4.67	10.31
Filing Date Shares Outstanding	86.27	28.04	21.99	16.97	4.54	4.53
Total Common Shares Outstanding	85.77	27.55	21.67	4.89	4.54	4.53
Working Capital	31.74	-1.85	7.91	13.88	18.49	43.67
Book Value Per Share	0.12	-1.02	0.43	1.41	4.10	9.69
Tangible Book Value	-9.63	-47.92	-39.14	-78.64	18.62	43.9
Tangible Book Value Per Share	-0.11	-1.74	-1.81	-16.10	4.10	9.69
Machinery	-	-	-	-	0.34	0.34

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 15, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 20, 2026

Data Sources Report a data error